| Code | CSB-RA003995MB6HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is a research-grade biosimilar to eculizumab-aeeb, designed to target complement component 5 (C5), a critical protein in the complement cascade of the innate immune system. C5 plays a pivotal role in immune defense by generating C5a, a potent anaphylatoxin and chemotactic factor, and C5b, which initiates formation of the membrane attack complex (MAC). Dysregulated C5 activation is implicated in various complement-mediated disorders, including paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), myasthenia gravis, and neuromyelitis optica spectrum disorders.
The reference antibody eculizumab-aeeb is a complement inhibitor that binds to C5, preventing its cleavage into C5a and C5b, thereby blocking terminal complement activation and MAC-mediated cell lysis. This biosimilar provides researchers with a valuable tool for investigating complement-mediated pathophysiology, studying C5-dependent immune responses, evaluating therapeutic mechanisms in complement disorders, and developing novel treatment strategies targeting the complement system.
There are currently no reviews for this product.